Pneumococcal disease burden in high-risk older adults: Exploring impact of comorbidities, long-term care facilities, antibiotic resistance, and immunization policies through a narrative literature review

Hum Vaccin Immunother. 2024 Dec 31;20(1):2429235. doi: 10.1080/21645515.2024.2429235. Epub 2024 Dec 4.

Abstract

This study aims to provide a comprehensive review of literature on pneumococcal disease burden in high-risk older adults aged ≥65 with focus on impact of comorbidities, long-term care facilities (LTCFs), antibiotic resistance, and vaccination policies across various countries. Research showed that the disease burden and the prevalence of antibiotic-resistant pneumococci was higher in the elderly, particularly those residing in LTCFs, and with comorbidities. These individuals are at high risk of infection with antibiotic-resistant serotypes 10A, 11A, and 15B. The vaccination strategies and national guidelines for pneumococcal vaccines in the elderly vary across countries. Some countries focus on single-dose strategies, while others recommend sequential vaccinations with varying intervals. Although vaccination policies are well-established for the elderly, they are not as well-established for high-risk elderly groups, and this review underscores the need for more tailored vaccination strategies for these groups.

Keywords: Pneumococcal disease; antibiotic resistance; high-risk elderly population; long-term care facility; serotype distribution; vaccination strategies.

Publication types

  • Review

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • Comorbidity*
  • Cost of Illness
  • Drug Resistance, Bacterial
  • Humans
  • Immunization Programs
  • Long-Term Care* / statistics & numerical data
  • Pneumococcal Infections* / epidemiology
  • Pneumococcal Infections* / prevention & control
  • Pneumococcal Vaccines* / administration & dosage
  • Pneumococcal Vaccines* / immunology
  • Prevalence
  • Serogroup
  • Streptococcus pneumoniae* / drug effects
  • Streptococcus pneumoniae* / immunology
  • Vaccination* / statistics & numerical data

Substances

  • Pneumococcal Vaccines
  • Anti-Bacterial Agents

Grants and funding

This manuscript was funded by the Pfizer Korea.